Fatty Liver After Menopause: The Risk Nobody Warns You About

Fatty liver becomes more common after menopause because estrogen is a metabolic regulator of the liver, and losing it changes where your body stores fat and how well your liver handles it.

The numbers are striking. An analysis of NHANES 2017-2020 data found steatotic liver disease in 34.6% of postmenopausal women compared with 23.5% of premenopausal women, with MASLD specifically accounting for 32.8% versus 21.7%. Before menopause, women have substantially lower rates of fatty liver than age-matched men. Afterwards, the rates converge and in some analyses exceed men's.

Four mechanisms drive it:

Visceral fat redistribution. Estrogen loss shifts fat storage from the hips and thighs to the abdominal cavity. Visceral fat is metabolically active and drains directly into the portal vein — meaning the free fatty acids it releases go straight to the liver rather than into general circulation. Our article on [why belly fat shifts in menopause](/blog/glp1-visceral-fat-menopause-belly-fat-guide) explains the redistribution in more detail.

Receptor switching in fat cells. Downregulation of estrogen receptors in visceral adipocytes leads to increased androgen receptor expression. The cells become more androgen-sensitive, which further promotes central fat accumulation — a self-reinforcing loop.

Insulin resistance. Estrogen supports insulin sensitivity in muscle and liver. Losing it means more circulating insulin, which drives hepatic de novo lipogenesis — the liver making fat from carbohydrate. This connects directly to [insulin resistance in menopause](/blog/glp1-menopause-insulin-resistance-the-connection).

Direct hepatic effects. Estrogen receptors in liver cells regulate lipid oxidation and export. Preclinical work shows estrogen deficiency alone promotes hepatic lipid accumulation, insulin resistance, and fibrosis independent of weight gain.

The practical upshot: you can gain relatively little weight through menopause and still develop fatty liver, because the problem is *where* the fat went and what your liver is doing with it.

MASLD stands for metabolic dysfunction-associated steatotic liver disease. It replaced the older term NAFLD (non-alcoholic fatty liver disease) in 2023, following an international consensus process.

The change was not cosmetic. NAFLD was a diagnosis of exclusion — fat in the liver, no significant alcohol intake, therefore NAFLD. It defined the condition by what it was *not*. MASLD defines it by what it is: liver fat plus at least one cardiometabolic risk factor, such as raised waist circumference, elevated blood glucose or type 2 diabetes, high blood pressure, raised triglycerides, or low HDL. Most postmenopausal women with fatty liver meet at least one of these easily.

The terms you will encounter:

• •Steatosis — fat in liver cells. The starting point. Often reversible.
• •MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) — fat plus inflammation and liver cell injury. This is the stage that progresses.
• •Fibrosis — scarring, graded F0 to F4. F4 is cirrhosis. Fibrosis stage is the single best predictor of liver-related death, which is why staging matters more than the fat itself.
• •MetALD — a new category for people with both metabolic risk factors and moderate alcohol intake. Relevant to plenty of midlife women, and worth knowing exists.

The renaming also removed a genuine clinical problem: 'non-alcoholic' made the conversation awkward and led some clinicians to skip it. Naming the metabolic driver makes the treatment target obvious.

One more distinction. Simple steatosis in isolation is not dangerous for most people. The concern is the minority who progress to MASH and then to fibrosis — and there is currently no way to tell from symptoms alone which group you are in.

Usually you don't, until something else finds it. MASLD is asymptomatic in the large majority of cases. When symptoms do occur they are vague and easily attributed to menopause itself: fatigue and a dull ache under the right ribs. That overlap is a real problem, because [menopausal fatigue](/blog/menopause-fatigue-why-youre-exhausted-and-what-helps) is common enough that nobody investigates it.

How it typically gets found:

An incidental ultrasound. A scan for gallstones or abdominal pain reports a 'fatty' or 'echogenic' liver.

Mildly raised liver enzymes. ALT slightly above range on routine bloodwork. Important caveat: normal liver enzymes do not rule out MASLD or even significant fibrosis. Many people with advanced disease have a completely normal ALT.

Proactive screening. Increasingly recommended for people with type 2 diabetes, obesity, or metabolic syndrome.

The FIB-4 score is the standard first-line risk calculation, and it is free. It uses four things you probably already have: age, AST, ALT, and platelet count. Plug them into any online FIB-4 calculator.

• •Under 1.3 — low risk of advanced fibrosis. Recheck in a few years.
• •1.3 to 2.67 — indeterminate. Needs a second test.
• •Above 2.67 — high risk. Needs specialist referral.

If FIB-4 is indeterminate or high, the next step is usually transient elastography (FibroScan), a painless ultrasound-based scan that measures liver stiffness, or an ELF blood test. Biopsy is now reserved for unclear cases.

A practical note: FIB-4 was validated in older populations and can over-call risk in people under 35 and under-call it in people over 65. It is a triage tool, not a diagnosis.

Worth asking for if you are postmenopausal with central weight gain, prediabetes, raised triglycerides, or a family history of liver disease. It costs nothing to calculate.

Yes — and this is now the strongest evidence in the field.

The ESSENCE trial, published in the *New England Journal of Medicine* in 2025, was a phase 3 study of semaglutide 2.4 mg in adults with MASH and moderate to advanced liver fibrosis. At 72 weeks, in the planned interim analysis:

• •Resolution of steatohepatitis with no worsening of fibrosis: 62.9% on semaglutide versus 34.3% on placebo — a 28.7 percentage point difference.
• •Improvement in liver fibrosis with no worsening of steatohepatitis: 36.8% versus 22.4% — a 14.4 point difference.
• •Both outcomes together: 32.7% versus 16.1%.

The fibrosis result is the significant one. Reversing established scarring is what the field has been chasing for two decades. Our dedicated breakdown of [the ESSENCE trial results](/blog/glp1-fatty-liver-mash-essence-trial-results) covers the methodology in more depth.

Why GLP-1s work here is straightforward once you see the mechanism. They produce substantial weight loss, and 7-10% body weight loss is the established threshold for MASH improvement. They preferentially reduce visceral fat, which is the compartment feeding the liver. They improve insulin sensitivity, cutting hepatic fat production. And there is likely a modest direct anti-inflammatory effect independent of weight.

For postmenopausal women specifically, the alignment is unusually good: the drug targets visceral fat and insulin resistance, which are precisely the two mechanisms estrogen loss activates.

Caveats worth holding. ESSENCE studied people with biopsy-proven MASH and fibrosis, not everyone with a fatty liver on ultrasound. The dual GIP/GLP-1 agonist tirzepatide has also shown MASH benefit in phase 2 (SYNERGY-NASH), with phase 3 ongoing. And the effect depends on staying on treatment — the [weight regain that follows stopping](/blog/stopping-a-glp1-tapering-and-weight-regain-what-to-expect) presumably takes liver fat with it, though long-term data is not yet in.

Plausibly, but the evidence is not strong enough to prescribe HRT for this reason alone.

The logic is sound. If estrogen deficiency drives MASLD, replacing estrogen should help. Observational studies do generally find lower rates of fatty liver in postmenopausal women using hormone therapy, and animal models show estrogen protects against hepatic steatosis and fibrosis.

But observational data on HRT is famously vulnerable to healthy-user bias — women who take HRT differ systematically from women who don't, in ways that also affect liver fat. And there are no randomized trials with liver histology as the primary endpoint. That is the trial the field needs and does not have.

One detail that does matter clinically: route of administration. Oral estrogen passes through the liver first and raises triglycerides. Transdermal estradiol — patch or gel — bypasses first-pass hepatic metabolism and does not. For a woman with fatty liver and raised triglycerides, transdermal is the more sensible route. This is worth raising specifically, because it is not always the default prescription.

What the honest position looks like: if you want HRT for vasomotor symptoms, sleep, or bone, and you also have fatty liver, that is a point in favour of taking it and a strong point in favour of transdermal delivery. If your only reason for considering HRT is your liver, the evidence does not currently justify it.

What definitely works, regardless:

• •7-10% weight loss — the best-established intervention, by any means.
• •Resistance training — reduces liver fat even without weight loss, partly by improving insulin sensitivity in muscle.
• •Cutting alcohol — MASLD and alcohol are additive, and the MetALD category exists precisely because the combination is common.
• •Reducing fructose from sweetened drinks — fructose is metabolised almost entirely in the liver and directly drives fat production.
• •Coffee — consistently associated with lower fibrosis risk across multiple cohorts. One of the few genuinely enjoyable items on any liver advice list.